Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics

Despite having the second highest mortality associated with cancer, currently Sorafenib is the only FDA-approved chemotherapeutic agent available for liver cancer patients which can only improve survival for few months. In this study, various pyrazolic chalcone analogous compounds were synthesized a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2017-03, Vol.129, p.12-26
Hauptverfasser: Hawash, Mohammed M.A., Kahraman, Deniz Cansen, Eren, Fikriye, Cetin Atalay, Rengul, Baytas, Sultan Nacak
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 26
container_issue
container_start_page 12
container_title European journal of medicinal chemistry
container_volume 129
creator Hawash, Mohammed M.A.
Kahraman, Deniz Cansen
Eren, Fikriye
Cetin Atalay, Rengul
Baytas, Sultan Nacak
description Despite having the second highest mortality associated with cancer, currently Sorafenib is the only FDA-approved chemotherapeutic agent available for liver cancer patients which can only improve survival for few months. In this study, various pyrazolic chalcone analogous compounds were synthesized and evaluated as potential chemotherapeutic agents for the treatment of hepatocellular carcinoma (HCC). Modifying the central pyrazole ring at the C(3)-position with different heteroaryl rings and substituting the C(4)-position of pyrazole with differently substituted chalcone moiety produced fouthy two variant compounds. For all these compounds, cytotoxicity was evaluated using sulforhodamine B assay and real time cell growth tracking, respectively. Based on 50% inhibitory concentration (IC50) values, compounds 39, 42, 49, and 52 were shown to exhibit potent cytotoxic activity against all the cancer cell lines tested, and had better cytotoxic activities than the well-known chemotherapeutic drug 5-FU. Therefore, these compounds were chosen to be further evaluated in a panel of HCC cell lines. Flow cytometric analysis of HCC cells treated with compounds 39, 42, 49, and 52 demonstrated that these compounds caused cell cycle arrest at G2/M phase followed by the apoptotic cell death and impaired cell growth as shown by real-time cell growth surveillance. Consistent with these results, western blotting of HCC cells treated with the compounds resulted in molecular changes for cell cycle proteins, where p21 levels were increased independent of p53 and the levels of the key initiators of mitosis Cyclin B1 and CDK1 were shown to decrease upon treatment. In conclusion, chalcone derivatives 42 and 52 show potent bioactivities by modulating the expression of cell-cycle related proteins and resulting in cell-cycle arrest in the HCC cell lines tested here, indicating that the compounds can be considered as preclinical candidates. [Display omitted] •A series of pyrazole chalcone derivatives was designed and synthesized.•39, 42, 49 and 52 significantly suppressed the cell proliferation in human cancer cell lines.•39, 42, 49 and 52 caused dramatic cell cycle arrest at G2/M phase producing apoptosis.
doi_str_mv 10.1016/j.ejmech.2017.02.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1870648642</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523417300673</els_id><sourcerecordid>1870648642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-98d02d25ce53b2b61b7ec084579380acb6b01309732b94a569f5bcd2a1ddf8053</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhq2Kqt0W_gFCPnJJGDuxk1yQUMVHpUocCmfLHxPWKycOdhJp--vJaheOnObyzPvOPIS8ZVAyYPLDocTDgHZfcmBNCbwE4FdkxxrZFhUX9SuyA86rQvCqviV3OR8AQEiAG3LLW846qOWOvDwfx3mP2WeqR0eNjyH-8lYHiqsOi559HGns6RhXDHQ6Jv0Sg7fU7nWwcUTqMPl1w1bcEvKF2-Ok52gxhCXoRK1O1o9x0HSrSnrCZfY2vybXvQ4Z31zmPfn55fOPh2_F0_evjw-fngpbST4XXeuAOy4sispwI5lp0EJbi6arWtDWSAOsgq6puOlqLWTXC2Md18y5vgVR3ZP359wpxd8L5lkNPp9u0yPGJSvWNiDrVtZ8Q-szalPMOWGvpuQHnY6KgTpZVwd1tq5O1hVwtVnf1t5dGhYzoPu39FfzBnw8A7j9uXpMKluPo0XnE9pZuej_3_AHKSWX_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1870648642</pqid></control><display><type>article</type><title>Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hawash, Mohammed M.A. ; Kahraman, Deniz Cansen ; Eren, Fikriye ; Cetin Atalay, Rengul ; Baytas, Sultan Nacak</creator><creatorcontrib>Hawash, Mohammed M.A. ; Kahraman, Deniz Cansen ; Eren, Fikriye ; Cetin Atalay, Rengul ; Baytas, Sultan Nacak</creatorcontrib><description>Despite having the second highest mortality associated with cancer, currently Sorafenib is the only FDA-approved chemotherapeutic agent available for liver cancer patients which can only improve survival for few months. In this study, various pyrazolic chalcone analogous compounds were synthesized and evaluated as potential chemotherapeutic agents for the treatment of hepatocellular carcinoma (HCC). Modifying the central pyrazole ring at the C(3)-position with different heteroaryl rings and substituting the C(4)-position of pyrazole with differently substituted chalcone moiety produced fouthy two variant compounds. For all these compounds, cytotoxicity was evaluated using sulforhodamine B assay and real time cell growth tracking, respectively. Based on 50% inhibitory concentration (IC50) values, compounds 39, 42, 49, and 52 were shown to exhibit potent cytotoxic activity against all the cancer cell lines tested, and had better cytotoxic activities than the well-known chemotherapeutic drug 5-FU. Therefore, these compounds were chosen to be further evaluated in a panel of HCC cell lines. Flow cytometric analysis of HCC cells treated with compounds 39, 42, 49, and 52 demonstrated that these compounds caused cell cycle arrest at G2/M phase followed by the apoptotic cell death and impaired cell growth as shown by real-time cell growth surveillance. Consistent with these results, western blotting of HCC cells treated with the compounds resulted in molecular changes for cell cycle proteins, where p21 levels were increased independent of p53 and the levels of the key initiators of mitosis Cyclin B1 and CDK1 were shown to decrease upon treatment. In conclusion, chalcone derivatives 42 and 52 show potent bioactivities by modulating the expression of cell-cycle related proteins and resulting in cell-cycle arrest in the HCC cell lines tested here, indicating that the compounds can be considered as preclinical candidates. [Display omitted] •A series of pyrazole chalcone derivatives was designed and synthesized.•39, 42, 49 and 52 significantly suppressed the cell proliferation in human cancer cell lines.•39, 42, 49 and 52 caused dramatic cell cycle arrest at G2/M phase producing apoptosis.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2017.02.002</identifier><identifier>PMID: 28219046</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Carcinoma, Hepatocellular - drug therapy ; Cell cycle ; Cell Cycle Checkpoints - drug effects ; Cell Cycle Proteins - drug effects ; Cell Cycle Proteins - metabolism ; Cell Line, Tumor ; Chalcone - chemical synthesis ; Chalcone - pharmacology ; Chalcone - therapeutic use ; Chalcone derivatives ; Cyclin B1/CDK1 inhibitors ; Cytotoxic activity ; G2 Phase - drug effects ; Hepatocellular carcinoma ; Humans ; Liver Neoplasms - drug therapy ; Pyrazoles ; Pyrazoles - chemical synthesis ; Pyrazoles - pharmacology ; Pyrazoles - therapeutic use ; Structure-Activity Relationship</subject><ispartof>European journal of medicinal chemistry, 2017-03, Vol.129, p.12-26</ispartof><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-98d02d25ce53b2b61b7ec084579380acb6b01309732b94a569f5bcd2a1ddf8053</citedby><cites>FETCH-LOGICAL-c362t-98d02d25ce53b2b61b7ec084579380acb6b01309732b94a569f5bcd2a1ddf8053</cites><orcidid>0000-0001-5640-9700</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523417300673$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28219046$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hawash, Mohammed M.A.</creatorcontrib><creatorcontrib>Kahraman, Deniz Cansen</creatorcontrib><creatorcontrib>Eren, Fikriye</creatorcontrib><creatorcontrib>Cetin Atalay, Rengul</creatorcontrib><creatorcontrib>Baytas, Sultan Nacak</creatorcontrib><title>Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Despite having the second highest mortality associated with cancer, currently Sorafenib is the only FDA-approved chemotherapeutic agent available for liver cancer patients which can only improve survival for few months. In this study, various pyrazolic chalcone analogous compounds were synthesized and evaluated as potential chemotherapeutic agents for the treatment of hepatocellular carcinoma (HCC). Modifying the central pyrazole ring at the C(3)-position with different heteroaryl rings and substituting the C(4)-position of pyrazole with differently substituted chalcone moiety produced fouthy two variant compounds. For all these compounds, cytotoxicity was evaluated using sulforhodamine B assay and real time cell growth tracking, respectively. Based on 50% inhibitory concentration (IC50) values, compounds 39, 42, 49, and 52 were shown to exhibit potent cytotoxic activity against all the cancer cell lines tested, and had better cytotoxic activities than the well-known chemotherapeutic drug 5-FU. Therefore, these compounds were chosen to be further evaluated in a panel of HCC cell lines. Flow cytometric analysis of HCC cells treated with compounds 39, 42, 49, and 52 demonstrated that these compounds caused cell cycle arrest at G2/M phase followed by the apoptotic cell death and impaired cell growth as shown by real-time cell growth surveillance. Consistent with these results, western blotting of HCC cells treated with the compounds resulted in molecular changes for cell cycle proteins, where p21 levels were increased independent of p53 and the levels of the key initiators of mitosis Cyclin B1 and CDK1 were shown to decrease upon treatment. In conclusion, chalcone derivatives 42 and 52 show potent bioactivities by modulating the expression of cell-cycle related proteins and resulting in cell-cycle arrest in the HCC cell lines tested here, indicating that the compounds can be considered as preclinical candidates. [Display omitted] •A series of pyrazole chalcone derivatives was designed and synthesized.•39, 42, 49 and 52 significantly suppressed the cell proliferation in human cancer cell lines.•39, 42, 49 and 52 caused dramatic cell cycle arrest at G2/M phase producing apoptosis.</description><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Cell cycle</subject><subject>Cell Cycle Checkpoints - drug effects</subject><subject>Cell Cycle Proteins - drug effects</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Chalcone - chemical synthesis</subject><subject>Chalcone - pharmacology</subject><subject>Chalcone - therapeutic use</subject><subject>Chalcone derivatives</subject><subject>Cyclin B1/CDK1 inhibitors</subject><subject>Cytotoxic activity</subject><subject>G2 Phase - drug effects</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Pyrazoles</subject><subject>Pyrazoles - chemical synthesis</subject><subject>Pyrazoles - pharmacology</subject><subject>Pyrazoles - therapeutic use</subject><subject>Structure-Activity Relationship</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhq2Kqt0W_gFCPnJJGDuxk1yQUMVHpUocCmfLHxPWKycOdhJp--vJaheOnObyzPvOPIS8ZVAyYPLDocTDgHZfcmBNCbwE4FdkxxrZFhUX9SuyA86rQvCqviV3OR8AQEiAG3LLW846qOWOvDwfx3mP2WeqR0eNjyH-8lYHiqsOi559HGns6RhXDHQ6Jv0Sg7fU7nWwcUTqMPl1w1bcEvKF2-Ok52gxhCXoRK1O1o9x0HSrSnrCZfY2vybXvQ4Z31zmPfn55fOPh2_F0_evjw-fngpbST4XXeuAOy4sispwI5lp0EJbi6arWtDWSAOsgq6puOlqLWTXC2Md18y5vgVR3ZP359wpxd8L5lkNPp9u0yPGJSvWNiDrVtZ8Q-szalPMOWGvpuQHnY6KgTpZVwd1tq5O1hVwtVnf1t5dGhYzoPu39FfzBnw8A7j9uXpMKluPo0XnE9pZuej_3_AHKSWX_Q</recordid><startdate>20170331</startdate><enddate>20170331</enddate><creator>Hawash, Mohammed M.A.</creator><creator>Kahraman, Deniz Cansen</creator><creator>Eren, Fikriye</creator><creator>Cetin Atalay, Rengul</creator><creator>Baytas, Sultan Nacak</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5640-9700</orcidid></search><sort><creationdate>20170331</creationdate><title>Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics</title><author>Hawash, Mohammed M.A. ; Kahraman, Deniz Cansen ; Eren, Fikriye ; Cetin Atalay, Rengul ; Baytas, Sultan Nacak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-98d02d25ce53b2b61b7ec084579380acb6b01309732b94a569f5bcd2a1ddf8053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Cell cycle</topic><topic>Cell Cycle Checkpoints - drug effects</topic><topic>Cell Cycle Proteins - drug effects</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Chalcone - chemical synthesis</topic><topic>Chalcone - pharmacology</topic><topic>Chalcone - therapeutic use</topic><topic>Chalcone derivatives</topic><topic>Cyclin B1/CDK1 inhibitors</topic><topic>Cytotoxic activity</topic><topic>G2 Phase - drug effects</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Pyrazoles</topic><topic>Pyrazoles - chemical synthesis</topic><topic>Pyrazoles - pharmacology</topic><topic>Pyrazoles - therapeutic use</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hawash, Mohammed M.A.</creatorcontrib><creatorcontrib>Kahraman, Deniz Cansen</creatorcontrib><creatorcontrib>Eren, Fikriye</creatorcontrib><creatorcontrib>Cetin Atalay, Rengul</creatorcontrib><creatorcontrib>Baytas, Sultan Nacak</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hawash, Mohammed M.A.</au><au>Kahraman, Deniz Cansen</au><au>Eren, Fikriye</au><au>Cetin Atalay, Rengul</au><au>Baytas, Sultan Nacak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2017-03-31</date><risdate>2017</risdate><volume>129</volume><spage>12</spage><epage>26</epage><pages>12-26</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Despite having the second highest mortality associated with cancer, currently Sorafenib is the only FDA-approved chemotherapeutic agent available for liver cancer patients which can only improve survival for few months. In this study, various pyrazolic chalcone analogous compounds were synthesized and evaluated as potential chemotherapeutic agents for the treatment of hepatocellular carcinoma (HCC). Modifying the central pyrazole ring at the C(3)-position with different heteroaryl rings and substituting the C(4)-position of pyrazole with differently substituted chalcone moiety produced fouthy two variant compounds. For all these compounds, cytotoxicity was evaluated using sulforhodamine B assay and real time cell growth tracking, respectively. Based on 50% inhibitory concentration (IC50) values, compounds 39, 42, 49, and 52 were shown to exhibit potent cytotoxic activity against all the cancer cell lines tested, and had better cytotoxic activities than the well-known chemotherapeutic drug 5-FU. Therefore, these compounds were chosen to be further evaluated in a panel of HCC cell lines. Flow cytometric analysis of HCC cells treated with compounds 39, 42, 49, and 52 demonstrated that these compounds caused cell cycle arrest at G2/M phase followed by the apoptotic cell death and impaired cell growth as shown by real-time cell growth surveillance. Consistent with these results, western blotting of HCC cells treated with the compounds resulted in molecular changes for cell cycle proteins, where p21 levels were increased independent of p53 and the levels of the key initiators of mitosis Cyclin B1 and CDK1 were shown to decrease upon treatment. In conclusion, chalcone derivatives 42 and 52 show potent bioactivities by modulating the expression of cell-cycle related proteins and resulting in cell-cycle arrest in the HCC cell lines tested here, indicating that the compounds can be considered as preclinical candidates. [Display omitted] •A series of pyrazole chalcone derivatives was designed and synthesized.•39, 42, 49 and 52 significantly suppressed the cell proliferation in human cancer cell lines.•39, 42, 49 and 52 caused dramatic cell cycle arrest at G2/M phase producing apoptosis.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>28219046</pmid><doi>10.1016/j.ejmech.2017.02.002</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-5640-9700</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2017-03, Vol.129, p.12-26
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_1870648642
source MEDLINE; Elsevier ScienceDirect Journals
subjects Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - pharmacology
Apoptosis
Apoptosis - drug effects
Carcinoma, Hepatocellular - drug therapy
Cell cycle
Cell Cycle Checkpoints - drug effects
Cell Cycle Proteins - drug effects
Cell Cycle Proteins - metabolism
Cell Line, Tumor
Chalcone - chemical synthesis
Chalcone - pharmacology
Chalcone - therapeutic use
Chalcone derivatives
Cyclin B1/CDK1 inhibitors
Cytotoxic activity
G2 Phase - drug effects
Hepatocellular carcinoma
Humans
Liver Neoplasms - drug therapy
Pyrazoles
Pyrazoles - chemical synthesis
Pyrazoles - pharmacology
Pyrazoles - therapeutic use
Structure-Activity Relationship
title Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A11%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20biological%20evaluation%20of%20novel%20pyrazolic%20chalcone%20derivatives%20as%20novel%20hepatocellular%20carcinoma%20therapeutics&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Hawash,%20Mohammed%20M.A.&rft.date=2017-03-31&rft.volume=129&rft.spage=12&rft.epage=26&rft.pages=12-26&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2017.02.002&rft_dat=%3Cproquest_cross%3E1870648642%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1870648642&rft_id=info:pmid/28219046&rft_els_id=S0223523417300673&rfr_iscdi=true